Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas (GlobeNewswire) - Sep 22, 2022 - "Plus Therapeutics, Inc...announced that it has finalized and signed a grant contract with the Cancer Prevention & Research Institute of Texas (CPRIT) for its previously announced $17.6 million Product Development Research funding award. The award will cover the majority of the development costs of the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM) over a three-year period, beginning in the fourth quarter of 2022."
Financing • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|